Effect of Dietary and Life Style Modification on Post Liver Transplant Obesity

Nonalcoholic Steatohepatitis Clinical Trial

Official title:

Effect of Dietary and Life Style Modification on Post Liver Transplant Obesity

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00878592
• Other study ID #: PRO08010154
• Secondary ID: non applicable
• Status: Terminated
• Phase: N/A
• First received: April 8, 2009
• Last updated: October 9, 2017
• Start date: October 2008

Study information

• Verified date: April 2009
• Source: University of Pittsburgh
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is to assess value of providing classes about dietary and life style modifications to decrease or prevent weight gain, less occurrence or better control of weight gain associated disorders such as high blood sugar, hypertension, heart or brain vessels problems.Candidates for this study will be those who have got liver transplant within 6 months of their post transplant period.

Description:

This study is designed to be an interventional, prospective, randomized, case-control clinical trial. Procedures will be done in Starzl Transplant Institute and Center for Liver disease, Kaufmann building, UPMC.

Subjects selected to participate in this study, are adult liver transplant recipients who had undergone one liver transplantation during 6 months before the time of inclusion. They must be able to communicate in English (to be able to independently follow directives and record their activities in recall diaries). Patients will be excluded from the study if they are under 18 years old, refuse to give a written consent to participate in the study, have received liver graft more than 6 months before time of inclusion, have psychological or nervous disorders, have cardiovascular or musculoskeletal health problems interfering with basic physical activity, or have any manifestation of hepatic failure such as ascites and hepatic encephalopathy. Patients will be removed from the study if they develop intolerance to the dietary and physical recommendations (e.g. remarkable fatigue).

Verifying the eligibility of patients for participation in the study will be done through reviewing data in medical history, physical examination and investigations included in the patients' medical records. Complete blood count, liver function tests, fasting glucose and lipid profile, imaging and histopathologic investigations, abdominal imaging, pathology reports of liver biopsy, stress ECG, echocardiography. These tests are performed for standard of care.

Subjects will be randomly grouped into groups by simple randomization method. One of the investigators will randomly pick one folded paper out of a plastic bag that contains folded papers labeled on the folded side with the number of the group.

The first group (Group 1) will include the control subjects. They will receive one session of dietary and behavioral education. The second group (Group 2) will be the interventional group. They will receive a weight management and life style modification program similar to what has been previously described (Kelley et al. 2004). The program will be presented by a registered dietitian at UPMC". It consists of up to 6 weekly sessions of nutritional and physical exercise education. These initial sessions will concentrate on lifestyle modifications program including healthy food selections, emphasizing reduced fat consumption (<=30% of daily calories) and restriction of proteins to create a daily negative energy balance of ~500 kcal/day. Participants will be encouraged to start with 10 minutes of outdoor or at home physical activity such as walking or cycling then gradually increase the activity duration up to 30 minutes daily. The dietitian will provide each subject with diary for daily recording of dietary intake and physical activity respectively. Following the initial 6-week program patients will attend follow up session every 6 months for 5 years for dietary and behavioral education and to check dietary and physical activity diaries, reinforce and encourage compliance with dietary and physical exercise recommendations, answer questions and address problems. Patients will be required to attend at least 60% of the follow up sessions on site with face to face education. Attempts will be made to schedule these sessions on the same day of their regular clinical follow up to facilitate compliance. Up to 40% of monthly follow up sessions may be provided on the phone for patients who cannot attend on site because of travel restraints. The dietitian will call the candidate within few days after the missing appointment to check and encourage compliance, check for changes in weight. Each session will be held for up to 1 hour at the health education room of center for liver diseases. All sessions will be with a registered dietitian.

Additional 5 cc of blood will be taken at routine blood draws done twice in the first month then every 6 months for 5 years. The total blood volume withdrawn from each subject in both study groups is 60 cc. Blood will be spinned down, then serum will be banked in -80° Celsius freezer. These banked serum will be used in future research work aiming to assess activity of inflammatory and fibrotic markers such as tumor necrosis factor alpha, interleukin 6, leptin, and adiponectin.

Stool samples will be taken from all patients before study intervention and every 12 weeks afterwards. Stool samples will be stored at -80 degree Celsius freezer for future PCR study of fecal microflra.

Jennifer Steel will assess stress for the study candidates through specific questionnaire before start of intervention of the study and every 12 weeks afterwards.

The following data will be collected every 6 months during follow up visits for both groups; anthropometric indices of obesity such as measurements of weight, height (for BMI calculation), waist circumference, hip circumference, skin fold thickness and mid-arm circumference, survival rate, morbidity events such as cardiovascular or cerbrovascular events, diabetes and hypertension. For the control group, anthropometric measures will be obtained from them when they return for their routine clinic visits. Midarm circumference and triceps skin fold thickness will be measured to the nearest 1 cm, on the left arm midway between the tip of the acromion and the tip of olecranon. Skinfold thicknesses will be measured at triceps (Oppert et al. 2002). Waist circumference will be measured midway between iliac crest and lowest rib margin, and hip circumference at the level of the greater trochanters (Han et al. 2001).

Histological scores of necro-inflammation (Ishak score) and steatosis (Dixon's scale) of the implanted liver will be assessed at 1 year post transplant. All pathological evaluation will be done on parts (allocated for the research purpose) of biopsies obtained as deemed necessary for routine care by clinical providers (e.g. at 1 year post liver transplant) and will be conducted by the same pathologist blinded to the experimental protocol.

Data will be compared between the 2 groups by Chi square test and student t test . Assuming a rate of obesity in the control group of 50% and a 50% reduction of obesity incidence in the interventional group, we estimate that a sample size of 58 per group is needed to detect the difference with 80% confidence and a p value < 0.05. A p< 0.05 will be considered significant.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 0
• Est. primary completion date: June 2010
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult liver transplant recipients

• Those who have undergone one liver transplantation during 3 months before the time of inclusion.

• Ability to communicate in English (to be able to independently follow directives and record their activities in recall diaries).

Exclusion Criteria:

• Patients under 18 years old

• refusal to give a written consent to participate in the study

• Those who received liver graft more than 3 months before time of inclusion

• Significant cardiovascular or musculoskeletal health problems interfering with basic physical activity

• Any manifestations of hepatic failure such as ascites and hepatic encephalopathy

• Patients will be removed from the study if they develop intolerance to the dietary and physical recommendations (e.g. remarkable fatigue).

Related Conditions & MeSH terms

• Fatty Liver
• Non-alcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis
• Obesity
• Post Liver Transplantation Obesity
• Post Liver Transplantation Weight Gain
• Weight Gain

Intervention

Behavioral:
• Dietary and life style modification
This group will receive a weight management and life style modification program. It consists of up to 6 weekly sessions of nutritional and physical exercise education. These initial sessions will concentrate on lifestyle modifications program including healthy food selections, emphasizing reduced fat consumption (<=30% of daily calories) and restriction of proteins to create a daily negative energy balance of ~500 kcal/day. Participants will be encouraged to start with 10 minutes of outdoor or at home physical activity such as walking or cycling then gradually increase the activity duration up to 30 minutes daily.

Locations

Country	Name	City	State
United States	Center for Liver Diseases, UPMC.	Pittsburgh	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
University of Pittsburgh

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	waist circumference		before starting intervention, then every 6 months, afterwards for up to 5 years
Primary	weight, height (for BMI calculation)		before starting intervention, then every 6 months, afterwards for up to 5 years
Secondary	skin fold thickness		before starting intervention, then every 6 months, afterwards for up to 5 years
Secondary	survival rate		anually for up to 5 years
Secondary	Co morbidity events		anually for up to 5 years
Secondary	histological scores of necro-inflammation (Ishak score) and steatosis (Dixon's scale) of the implanted liver.		at 1 year from start of inclusion